Core Insights - Halozyme Therapeutics, Inc. (NASDAQ:HALO) is recognized as a highly profitable biotech stock with a maintained Buy rating and a price target of $90 by H.C. Wainwright analyst Mitchell Kapoor [1][2] Company Overview - Halozyme Therapeutics, Inc. operates as a biopharmaceutical technology platform company, focusing on the development, manufacturing, and commercialization of drug-device combination products utilizing advanced auto-injector technology [4] Growth Potential - The company's growth potential is supported by the recent success of the MajesTEC-3 trial, which demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) compared to existing treatments [2][3] - The MajesTEC-3 trial combines Johnson & Johnson's DARZALEX Faspro with TECVAYLI, enhancing Halozyme's royalty base and providing strong evidence for DARZALEX-based regimens, which leverage the company's ENHANZE technology [3]